Introduction
Brukinsa (zanubrutinib) and Jaypirca (pirtobrutinib) are two targeted cancer therapies used to treat Chronic Lymphocytic Leukemia (CLL). Over the last decade, CLL has transitioned from chemotherapy to targeted therapies that attack specific pathways which cancer cells use to survive and proliferate. These two new treatments are part of the next generation of BTK inhibitors and have specific profiles of efficacy for patients with this disease.
